The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma.
Anne OlbrichJohannes NiemeyerHendrik SeiffertSebastian EbelOlga GrosFlorian LordickDirk ForstmeyerDaniel SeehoferSebastian RademacherTimm DeneckeMadlen Matz-SojaThomas BergFlorian van BoemmelPublished in: Journal of cancer research and clinical oncology (2024)
The GALAD score as well as the BALAD-2 score hold significant promise as a prognostic tool for patients with early or intermediate-stage HCC who are undergoing transarterial or systemic treatments.